{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-017549","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2023-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.058378+00:00","generated_at":"2026-06-20T07:15:48.974224+00:00","sec_items":["1.01","5.02"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Quince Therapeutics sells protease inhibitor portfolio to Lighthouse Pharma for up to $150M milestones","bullets":["Received 7.5% of Lighthouse common stock; eligible for up to $150M in milestone payments.","Royalties: high single-digit to mid-teens on clinical-stage programs; low single-digit on preclinical.","Exclusive option to obtain rights to COR388 for animal health until June 30, 2023.","No salary increases for 2023; executives granted stock options: CEO 600k, others 110k-225k, vesting monthly over 4 years.","2022 bonus payouts: CEO $169,287, CAO $137,185, CMO $116,962, CBO $104,650."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-017549","json":"https://secwatch.observer/filing/0001193125-23-017549.json","markdown":"https://secwatch.observer/filing/0001193125-23-017549.md","text":"https://secwatch.observer/filing/0001193125-23-017549.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523017549/0001193125-23-017549-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523017549/d453314d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T07:15:48.974224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4318a5ea6ebd3307474e82daf17c91b7a0591fd1","claim":"Quince Therapeutics, Inc. entered into Asset Purchase Agreement with Lighthouse Pharmaceuticals, Inc. valued at up to $150 million (effective 2023-01-27).","evidence_excerpt":"On January 27, 2023, Quince Therapeutics, Inc. (the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Lighthouse Pharmaceuticals, Inc. (“ Purchaser ”) for the sale of its legacy small molecule protease inhibitor portfolio for all uses and indications throughout the world","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523017549/0001193125-23-017549-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Lighthouse Pharmaceuticals, Inc."},{"label":"Value","value":"up to $150 million"},{"label":"Effective","value":"2023-01-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}